Prospective cytomegalovirus monitoring during first-line chemotherapy in patients with acute myeloid leukemia.
Little is known about the incidence and clinical impact of cytomegalovirus (CMV) infection in patients with acute myeloid leukemia at the time of diagnosis and during chemotherapy. The aims of the present study were to assess prospectively the incidence of active CMV infection in 69 consecutive patients with acute myeloid leukemia and to describe the outcomes of treatment. pp65 antigenemia was monitored at diagnosis, post-induction and post-consolidation chemotherapy, and whenever CMV reactivation was suspected. Patients with pp65 antigenemia received pre-emptive anti-CMV treatment. Fifty-nine patients achieved complete remission. Baseline CMV serology results were available for 56 of the 59 patients: 52 patients (93%) were IgG positive. The overall incidence of pp65 antigenemia in patients in complete remission after chemotherapy was 35% (21/59): 9 patients after induction and 12 post-consolidation. Sixteen of the 21 pp65-positive patients received anti-CMV treatment: 15 as pre-emptive therapy and 1 for interstitial CMV pneumonitis. Five patients received no anti-CMV treatment and did not develop CMV disease. Patients with pp65 antigenemia had more hospital admissions (2.57 vs. 2.16; P = 0.009), while patients with >10 pp65-positive cells had more clinical complications (8/9 vs. 2/12; P = 0.002). In conclusion, patients with acute myeloid leukemia receiving chemotherapy should be monitored for active CMV infection. CMV reactivation in these patients was associated with an increased number of hospital admissions, and high levels of pp65 antigenemia were associated with more clinical complications. Controlled studies are needed to assess the relevance of pre-emptive anti-CMV therapy in patients with acute myeloid leukemia receiving chemotherapy.
Capria
Saveria
S
Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University of Rome, Rome, Italy.
Gentile
Giuseppe
G
Capobianchi
Angela
A
Cardarelli
Luisa
L
Gianfelici
Valentina
V
Trisolini
Silvia Maria
SM
Foà
Robin
R
Martino
Pietro
P
Meloni
Giovanni
G
D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000914:Antibodies, Viral / Q000097:blood; D000956:Antigens, Viral / Q000097:blood; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use*; D003561:Cytarabine / Q000627:therapeutic use*; D003587:Cytomegalovirus / Q000276:immunology / Q000302:isolation & purification*; D003586:Cytomegalovirus Infections / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology*; D003630:Daunorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D015994:Incidence; D007558:Italy / Q000453:epidemiology; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000821:virology*; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D010750:Phosphoproteins / Q000097:blood; D016896:Treatment Outcome; D014763:Viral Matrix Proteins / Q000097:blood; D055815:Young Adult
D000903:Antibiotics, Antineoplastic; D000914:Antibodies, Viral; D000956:Antigens, Viral; D000970:Antineoplastic Agents; D000998:Antiviral Agents; D010750:Phosphoproteins; D014763:Viral Matrix Proteins; C065418:cytomegalovirus matrix protein 65kDa; D003561:Cytarabine; D006918:Hydroxyurea; D003630:Daunorubicin